FPE021 / FAPON - LARVOL DELTA

Trispecific TCE with second signal boosts bolid tumor response efficacy, durability and safety (AACR 2026) - "Furthermore, the integration of the second signal effectively enhances T-cell proliferation and mitigates T-cell apoptosis. Collectively, FPE021 represents a promising therapeutic strategy to overcome the current barriers limiting TCE efficacy in solid tumor treatment."

Clinical • Trispecific • Hematological Malignancies • Oncology • Solid Tumor • CDH17

Fapon Biopharma to Showcase Differentiated Pipeline, Including Phase 1 Immunocytokine FP008, and Innovative Technology Platforms at BIO 2025 (PRNewswire) - "Fapon Biopharma...is pleased to announce its participation in the BIO International Convention 2025 (BIO 2025), taking place June 16-19 in Boston Convention & Exhibition Center. The company will exhibit at Booth #1851, presenting its differentiated pipeline, including the flagship Phase 1 immunocytokine FP008, a portfolio of promising early-stage candidates for oncology and autoimmune diseases, and its suite of proprietary technology platforms, while actively seeking global partnerships...The company will also feature promising preclinical candidates targeting oncology (FP010, FP011, FPE021) and autoimmune diseases (FPE022, FPE024), highlighting its expanding research capabilities."

P1 data • Preclinical • Immunology • Solid Tumor